synthesize

```json
{
  "ranked_hypotheses": [
    {
      "rank": 1,
      "id": "H2",
      "title": "Enhancing Mitophagy Selectivity in Donor Astrocytes",
      "theorist_confidence": 0.68,
      "skeptic_confidence": 0.52,
      "expert_feasibility": 5,
      "composite_score": 0.55,
      "dimensions": {
        "mechanistic_plausibility": 0.72,
        "evidence_strength": 0.58,
        "novelty": 0.65,
        "feasibility": 0.62,
        "therapeutic_potential": 0.70,
        "druggability": 0.58,
        "safety_profile": 0.48,
        "competitive_landscape": 0.55,
        "data_availability": 0.52,
        "reproducibility": 0.58
      },
      "evidence_for": [
        {"claim": "PINK1/Parkin pathway selectively tags damaged mitochondria for degradation", "pmid": "15314227"},
        {"claim": "PINK1/Parkin pathway selectively tags damaged mitochondria for degradation", "pmid": "16906128"},
        {"claim": "Parkinson's disease astrocytes exhibit impaired mitophagy", "pmid": "31100121"},
        {"claim": "Enhancing mitophagy in astrocytes improves neuronal co-culture survival", "pmid": "31315049"},
        {"claim": "Astrocytic mitochondrial transfer can be protective in the short-term but damaging with accumulated dysfunction", "pmid": "26709160"},
        {"claim": "PINK1 is a serine/threonine kinase—an established drug target class with precedent for small molecule modulation", "pmid": null}
      ],
      "evidence_against": [
        {"claim": "PINK1 and PRKN mutations cause mitochondrial accumulation of dysfunction in neurons, but astrocyte-specific effects are less characterized", "pmid": "24514655"},
        {"claim": "Parkinson overexpression in mouse models does not consistently prevent neurodegeneration in non-PINK1 contexts", "pmid": "24514655"},
        {"claim": "Enhancing mitophagy in aged cells may not restore already-damaged mtDNA", "pmid": null},
        {"claim": "The fundamental assumption—that if damaged mitochondria are removed, only healthy ones remain for transfer—requires that astrocytes choose which mitochondria to release. No evidence currently establishes selective release based on mitochondrial quality status", "pmid": null},
        {"claim": "PINK1 enhancement in PD patients assumes reduced PINK1 activity is the primary defect, which may not be true in sporadic PD", "pmid": null}
      ],
      "key_gaps": [
        "No direct evidence that enhancing astrocyte mitophagy prevents transfer of damaged mitochondria specifically",
        "Whether astrocytes selectively release quality-controlled mitochondria is unproven",
        "PINK1 enhancement may not address upstream causes of mitophagy impairment in sporadic PD"
      ],
      "recommended_experiments": [
        "Use mt-Keima or similar mitophagy reporters in astrocytes, enhance PINK1/Parkin, then track which mitochondria (damaged vs. healthy) are actually transferred to neurons",
        "Astrocyte-specific Parkin transgenic with neurodegeneration models to test if enhanced astrocyte mitophagy prevents neuron loss",
        "Block transfer after mitophagy enhancement to test whether removing damaged mitochondria prevents transfer of damaged organelles"
      ]
    },
    {
      "rank": 2,
      "id": "H5",
      "title": "Targeting Mitochondrial-Derived Vesicles for Selective Cargo Sorting",
      "theorist_confidence": 0.65,
      "skeptic_confidence": 0.55,
      "expert_feasibility": 4,
      "composite_score": 0.51,
      "dimensions": {
        "mechanistic_plausibility": 0.60,
        "evidence_strength": 0.52,
        "novelty": 0.80,
        "feasibility": 0.52,
        "therapeutic_potential": 0.62,
        "druggability": 0.45,
        "safety_profile": 0.50,
        "competitive_landscape": 0.42,
        "data_availability": 0.48,
        "reproducibility": 0.50
      },
      "evidence_for": [
        {"claim": "MDVs selectively remove oxidized proteins and mitochondria-associated amyloid-beta", "pmid": "29733965"},
        {"claim": "PGC-1α regulates mitochondrial quality control and MDV production", "pmid": "28179766"},
        {"claim": "Amyloid-beta accumulates within astrocyte mitochondria in AD models", "pmid": "28903432"},
        {"claim": "PGC-1α is downregulated in AD astrocytes, reducing mitochondrial quality control", "pmid": "31439777"}
      ],
      "evidence_against": [
        {"claim": "MDV pathway for amyloid-beta removal has not been directly linked to mitochondrial transfer mechanisms", "pmid": null},
        {"claim": "PGC-1α agonists have pleiotropic effects beyond MDV biogenesis", "pmid": null},
        {"claim": "Whether MDV sorting excludes amyloid-beta from transferred mitochondria specifically is unestablished", "pmid": null}
      ],
      "